Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks



Status:Completed
Conditions:Vaccines, Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:2/6/2019
Start Date:October 27, 2016
End Date:November 26, 2018

Use our guide to learn which trials are right for you!

Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

The purpose of this study is to evaluate the clinical consistency of three production lots of
the Porcine circovirus (PCV)-free liquid formulation of oral live attenuated human rotavirus
(HRV) vaccine and to evaluate the PCV-free liquid formulation of HRV vaccine as compared to
the currently licensed lyophilised formulation of the HRV vaccine in terms of immunogenicity,
reactogenicity and safety when administered as a two-dose vaccination in healthy infants
starting at age 6-12 weeks. No new subjects will be enrolled in the extension phase of the
study

- Experimental design: Phase IIIA, observer-blind, randomised (1:1:1:1), controlled,
multi-centric, with four parallel groups and a staggered enrolment (Part A and Part B).

- Duration of the study: The intended duration of the study, per subject, will be
approximately 7-8 months including the 6 months of extended safety follow-up period
after the last dose of HRV vaccine.

- Epoch 001: Primary starting at Visit 1 (Day 0) and ending at the safety follow-up
contact (Month 7-8).

- Primary completion Date (PCD): Visit 3 (Month 2-4).

- End of Study (EoS): Last testing results released of samples collected at Visit 3 or
Last Subject Last Visit (LSLV) (Follow up contact at month 7-8).

- Study Groups:

- PCV-free HRV liquid formulation lot A (also referred to as Liq_A Group)

- PCV-free HRV liquid formulation lot B (also referred to as Liq_B Group)

- PCV-free HRV liquid formulation lot C (also referred to as Liq_C Group)

- GSK Biologicals' currently licensed lyophilised HRV formulation (also referred to
as Lyo Group)

- Control:active control-GSK Biologicals' currently licensed lyophilised HRV vaccine

- Vaccination schedule: Two doses of HRV vaccine to be administered according to a 0, 1-2
month schedule according to the immunisation schedule for RV vaccine.

Inclusion Criteria:

- Subjects' parent(s)/LAR(s) who, in the opinion of the investigator can and will comply
with the requirements of the protocol.

- Written informed consent obtained from the parent(s)/LAR(s) (Legally acceptable
representatives) of the subject prior to performing any study specific procedure.

- A male or female infant between, and including, 6 and 12 weeks (42-90 days) of age at
the time of the first study vaccination.

- Born full-term (i.e., between a gestation period of 37 weeks 0 days and 41 weeks 6
days).

- Healthy subjects as established by medical history and clinical examination before
entering into the study.

Exclusion Criteria:

- Child in care

- Use of any investigational or non-registered product other than the study vaccines
during the period starting 30 days before the first dose of study vaccines (Day-29 to
Day 0), or planned use during the study period.

- Chronic administration of immunosuppressants or other immune-modifying drugs since
birth. For corticosteroids, this will mean prednisone (0.5 mg/kg/day, or equivalent).
Inhaled and topical steroids are allowed.

- Administration of immunoglobulins and/or any blood products since birth or planned
administration during the study period.

- Administration of long-acting immune-modifying drugs at any time during the study
period.

- Planned administration/administration of a vaccine not foreseen by the study protocol
in the period starting 30 days before the first dose of vaccine administration and
ending at Visit 3, with the exception of the inactivated influenza vaccine, which is
allowed at any time during the study and other licensed routine childhood
vaccinations.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational vaccine/product.

- Uncorrected congenital malformation of the gastrointestinal tract that would
predispose for Intussusception (IS).

- History of IS.

- Family history of congenital or hereditary immunodeficiency.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination.

- Major congenital defects or serious chronic illness.

- Previous vaccination against RV.

- Previous confirmed occurrence of RVGE.

- GE within 7 days preceding the study vaccine administration.

- History of any reaction or hypersensitivity likely to be exacerbated by any component
of the vaccines.

- Hypersensitivity to latex.

- Acute disease and/or fever at the time of enrolment.

- Fever is defined as temperature ≥38.0°C/100.4°F. The preferred location for
measuring temperature in this study will be the oral cavity, the axilla and the
rectum.

- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory
infection) without fever may be enrolled at the discretion of the investigator.
We found this trial at
20
sites
Newton, Kansas 67114
Phone: 877-379-3718
?
mi
from
Newton, KS
Click here to add this to my saved trials
Anaheim, California 92807
Phone: 877-379-3718
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Birmingham, Alabama 35249
Phone: 877-379-3718
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cheraw, South Carolina 29520
Phone: 877-379-3718
?
mi
from
Cheraw, SC
Click here to add this to my saved trials
Cleveland, Ohio 44195
Phone: 877-379-3718
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Erie, Pennsylvania 16507
Phone: 877-379-3718
?
mi
from
Erie, PA
Click here to add this to my saved trials
Kansas City, Missouri 64128
Phone: 877-379-3718
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Layton, Utah 84041
Phone: 877-379-3718
?
mi
from
Layton, UT
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
Phone: 877-379-3718
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
Murray, Utah 84107
Phone: 877-379-3718
?
mi
from
Murray, UT
Click here to add this to my saved trials
Nampa, Idaho 83686
Phone: 877-379-3718
?
mi
from
Nampa, ID
Click here to add this to my saved trials
North Charleston, South Carolina 29456
Phone: 877-379-3718
?
mi
from
North Charleston, SC
Click here to add this to my saved trials
Orem, Utah 84058
Phone: 877-379-3718
?
mi
from
Orem, UT
Click here to add this to my saved trials
Paramount, California 90723
Phone: 877-379-3718
?
mi
from
Paramount, CA
Click here to add this to my saved trials
Provo, Utah 84604
Phone: 877-379-3718
?
mi
from
Provo, UT
Click here to add this to my saved trials
Sacramento, California 95815
Phone: 877-379-3718
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
San Jose, California 95116
Phone: 877-379-3718
?
mi
from
San Jose, CA
Click here to add this to my saved trials
San Jose, San José
Phone: 877-379-3718
?
mi
from
San Jose,
Click here to add this to my saved trials
Syracuse, Utah 84075
Phone: 877-379-3718
?
mi
from
Syracuse, UT
Click here to add this to my saved trials
Topeka, Kansas 66604
Phone: 877-379-3718
?
mi
from
Topeka, KS
Click here to add this to my saved trials